Bodycote Health Sciences acquires Prova

UK company Bodycote Health Sciences has further strengthened its pharmaceutical testing capabilities with the acquisition of Prova, the Camberley-based contract development laboratory. A leading providers of testing services to industry, Bodycote has pharmaceutical testing laboratories in Edinburgh, Windsor and Sittingbourne in Kent.

Independent contract development and testing organisation Prova was established in 1990 to provide analytical, development and regulatory support to the pharmaceutical and biotechnology industries. In addition to the pharmaceutical industry, it works with multinational companies in the field of biotechnology as well as OTC, generic and veterinary medicines. Prova is approved by the MHRA for QC testing as well as by the GLP Monitoring Authority.

'The acquisition of Prova strengthens our offering to the pharmaceutical industry with the addition of pre-formulation, formulation and regulatory services in the areas of licence applications, preparation of drug master files, technical dossiers and quality overall summaries,' said David Clapperton, managing director of Bodycote Health Sciences.

'Prova also takes us into the lucrative biotechnology market with the addition of biological analysis for antibodies, peptide hormones, receptor proteins and cell vaccines. The addition of Regulatory Services will provide welcome support to the existing Bodycote client base.'